State Street SPDR S&P China ETFGXC

State Street Investment Management has rebranded its ETF division, but the fund at the heart of today’s story-GXC, the SPDR S&P China ETF-still does exactly what it did on day one: it tracks the S&P China BMI Index, a basket of about 800 large- and mid-cap Chinese equities, with a 0.59% expense ratio that State Street markets as ‘competitive.’ The issuer’s own site now flogs the rebrand as ‘original solutions and better outcomes for all investors,’ which is investor-relations prose for a fund that charges more than many rivals to own the same stocks. The fund’s top holdings are the usual suspects: Tencent at 10.3%, Alibaba at 8.7%, Meituan at 4.2%, and a coterie of state-linked banks that make the fund’s ‘market access’ pitch feel more like a geopolitical hedge than a pure China play.

The S&P China BMI Index is licensed by State Street from S&P Dow Jones Indices LLC, so every quarterly rebalance and methodological tweak lands directly in GXC’s lap. The issuer’s fund-finder page insists SPDR ETFs offer ‘wide access to diverse investment opportunities,’ yet the fund’s structure is a weekly reweighting tax on Chinese consumer exposure, delivered through a wrapper that charges 0.59% for the privilege of tracking an index it did not create. The fund’s dividend distributions are routed through State Street Global Markets, LLC-State Street’s captive broker-dealer-which takes its cut before the net lands in your account, because in the SPDR world, the middleman is always invited to the party.

The fund’s AUM and liquidity figures are not disclosed in the supplied evidence, but the issuer’s site confirms State Street Investment Management’s aggregate ETF AUM of $1,940.32 billion as of March 31 2026, with $184.18 billion tied up in SPDR gold products. The fund-finder rail lists GXC alongside sector and ‘smart beta’ variants, none of which changes the fact that GXC is a passive China equity wrapper priced like an active fund. State Street Global Advisors Funds Distributors, LLC acts as distributor for some registered products on behalf of the adviser, so the filing trail chain is long, the fees are layered, and the underlying index method is the only thing that is, in fact, passive.

For investors who want to see the fund’s top holdings, concentration risk, or tracking error, the SEC EDGAR search for GXC provides the latest N-PORT filing, while Nasdaq’s market activity page shows daily turnover and spreads. The issuer’s dividend distribution calendar lists GXC’s declared payouts, but the filing does not separate GXC’s specific AUM or cash flows from the broader SPDR suite. The FINRA Fund Analyzer can break down the fund’s fee stack, but it cannot tell you whether the index it tracks is the best way to play Chinese consumer growth-or whether State Street’s marketing team will pivot next week to ‘AI-driven China exposure’ and charge you twice as much for the same stocks.

The S&P China BMI Index methodology is not reproduced in the supplied evidence, so the precise rules for inclusion, weighting, and rebalancing remain a black box unless you download the index methodology from S&P DJI’s site. State Street’s sitemap confirms the existence of sector and ‘premium income’ variants, but none of these pages reveal GXC’s tracking difference or the fund’s actual replication method (physical or synthetic). The issuer’s fund-finder page promises ‘diverse investment opportunities,’ yet the only diversity on offer is the choice between paying 0.59% for GXC or 0.29% for a plain MSCI China ETF that owns nearly the same names.

What changed today: the issuer’s brand changed, but the fund did not. The evidence contains no earnings surprises, no filing updates specific to GXC, and no named public development that alters the fund’s mandate or holdings. Until the next index rebalance or a State Street fee update, GXC remains a China equity ETF priced like a thematic fund, wrapped in SPDR branding and a 0.59% fee-because in the SPDR world, the wrapper is the real product.